Oppenheimer analyst, Wendy Lam, trimmed her price target on Gilead Sciences (NASDAQ: GILD) as the increasing volume of Harvoni ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE